Company intelligence / Profile preview

HexaBio

Ownership: Private
Employees: ~60
Development stage: Other

Overview

HexaBio is a biotechnology company specializing in the development of circular RNA (circRNA) therapeutics. The company leverages its proprietary Hexa-circRNA platform to design RNA molecules that are more stable and less immunogenic than traditional linear mRNA. This technology allows for prolonged protein expression, which is critical for treating chronic diseases and improving vaccine efficacy. HexaBio's current pipeline includes programs in oncology, infectious diseases, and protein replacement therapies. The company is headquartered in Singapore with significant research and development operations in China. HexaBio aims to translate its cutting-edge RNA engineering into transformative medicines for patients worldwide.

Therapeutic areas: OncologyRare DiseasesInfectious Diseases
Modalities: RNA therapyBiologicmRNA-based drugsLipid nanoparticle delivery therapy
Industry: Biotech

Beyond the preview

Go deeper on HexaBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HexaBio.